Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mg
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Nasal Congestion
Conditions
Nasal Congestion
Trial Timeline
Nov 1, 2006 → May 1, 2007
NCT ID
NCT00648973About Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mg
Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mg is a approved stage product being developed by Johnson & Johnson for Nasal Congestion. The current trial status is completed. This product is registered under clinical trial identifier NCT00648973. Target conditions include Nasal Congestion.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00648973 | Approved | Completed |
Competing Products
20 competing products in Nasal Congestion